Biodesix announces presentation on sars-cov-2 neutralizing antibody testing for individual vaccine response and commercial launch plans

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership with genscript biotech corporation, a webinar to present novel data on the rapid detection of total sars-cov-2 neutralizing antibodies using cpass™ technology. neutralizing antibodies may specifically block the interaction between the receptor binding protein on sars-cov-2, and the host cell's membrane receptor protein, t
BDSX Ratings Summary
BDSX Quant Ranking